CAS: 89796-99-6; 2-(2-(2-((2,6-Dichlorophenyl)Amino)Phenyl)Acetoxy)Acetic Acid

该化合物是一种主要用于其止痛和抗炎特性的非类固醇抗炎药物(NSAID),其特征是能够抑制酶环氧基酶(COX),该酶在合成蛋白腺素,炎症和疼痛的调解者方面起着关键作用.Aceclofenac通常以口服方式施用,以其相对迅速的行动开始和长期的治疗效果而著称.该物质经常用于治疗诸如骨髓炎,风湿类关节炎和其他肌肉骨骼紊乱等症状.其化学结构包括一种苯乙酸衍生物(COX),该物质在合成蛋白质,炎症和疼痛的调解中起着至关重要的作用.Aclofenac一般被很好地点,但与其他非甲状腺炎一样,它可能会造成胃肠侧效应,并且应当谨慎地用于治疗有肿瘤或肾脏损伤历史的病人.此外,在进行其他抗癌或肾脏损伤史的病人的治疗时,重要的是要考虑其潜在性反应,同时考虑其潜在性反应是用于对化学反应的,同时,而具有估价性反应.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号139272-68-7 2-(tert-butoxy)... | CAS号15307-79-6 双氯芬酸钠 | CAS号100499-89-6 醋氯芬酸苄酯 | CAS号139272-66-5 Aceclofenac met... | CAS号15307-86-5 双氯芬酸

合成工艺路线路线简述

    Tert-Butyl-[2-(2,6-Dichloroanilino) Phenyl] Acetoxy Acetate置于甲酸,三氟乙酸体系中,用 甲苯 作为反应溶剂,化学反应 5.5H,反应生成 醋氯芬酸
    参考文献: A Process For The Preparation Of [2-(2,6-Dichloro Anilino) Phenyl] Acetoxy Acetic Acid[fr] Procede De Preparation D'Acide [2-(2,6-Dichloro Anilino) Phenyl] Acetoxy Acetique
    标题: A Process For The Preparation Of [2-(2,6-Dichloro Anilino) Phenyl] Acetoxy Acetic Acid[fr] Procede De Preparation D'Acide [2-(2,6-Dichloro Anilino) Phenyl] Acetoxy Acetique
    摘要:提供了一种制备2-(2,6-二氯苯胺基)苯乙氧基乙酸的制造工艺.该工艺包括在强酸阳离子交换树脂的存在下,在溶剂存在的条件下,通过酸水解2-叔丁氧基-2-氧乙基{2-[(2,6-二氯苯基)氨基]苯基)乙酸酯,得到化合物的公式1.所得化合物显示出非甾体抗炎活性.

    海关参考信息

    专利信息


    专利号:US-2012177593-A1
    优先权日:2009-07-20
    标 题 :Synthesis of dendrimer conjugates
    发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
    权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-8304409-B2
    优先权日:2002-07-03
    标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
    发明人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
    权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
    摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

    专利号:US-9051302-B2
    优先权日:2008-01-15
    标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
    发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
    权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
    摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

    专利号:US-2023047214-A1
    优先权日:2020-02-03
    标题:Methods for microwave synthesis of degradable polymers for drug delivery
    发明人:MURATOGLU ORHUN K; ORAL EBRU; GRINDY SCOTT
    权利人:MASSACHUSETTS GEN HOSPITAL
    摘要:Provided herein are methods of making degradable, additive-blended polymeric materials using microwave radiation and catalysts. The methods can include incorporation of therapeutic materials into the polymeric materials. There also are provided polymeric materials made by the methods and medical devices comprising the polymeric materials made by the methods.

    专利号:US-2024287041-A1
    优先权日:2021-05-20
    标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
    发明人:BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN
    权利人:KARYOPHARM THERAPEUTICS INC
    摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.
    上海齐奥化工科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.qiaochem.com
    企业联系电话:021-50396381;50940968;58892003👤
    📞上海齐奥化工科技有限公司 ⚠️参考联系方式
    联系人:徐先生
    电话:021-50396381;50940968;58892003

    传真:021-50396382
    邮箱:aaron@qiaochem.com
    通信地址: 上海浦东新区张江环科路515号1号楼910室
    邮编: 201315
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:上海浦东新区张江环科路515号1号楼910室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    陕西大生制药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.dashengpharm.com
    企业联系电话:029-88193559👤
    📞陕西大生制药科技有限公司 ⚠️参考联系方式
    联系人:于先生
    电话:029-88193559
    手机:13384983898
    传真:QQ :2914631998
    邮箱:info@dashengpharm.com
    通信地址: 西安市高新区沣惠南路2号杰座广场9楼
    邮编: 710075
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:西安市高新区沣惠南路2号杰座广场9楼
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    苏州市立德化学有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.leaderchem.com
    电话: 0512-68412652 68087787👤
    📞苏州市立德化学有限公司 ⚠️参考联系方式

    销售电话:0512-68412652 68087787
    邮箱:sales@leaderchem.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    湖北恒硕化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hengshuochem.com
    企业联系电话:027-82200625;82830253👤
    📞湖北恒硕化工有限公司 ⚠️参考联系方式
    联系人:王硕 徐文琪
    电话:027-82200625;82830253
    手机:13986271535;13995541600
    传真:027-82830253
    邮箱:hengshuochem@163.com
    通信地址: 湖北省武汉市临空港经济技术开发区碧水大道7号飘轩工业园
    邮编: 430014
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:湖北省武汉市临空港经济技术开发区碧水大道7号飘轩工业园
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    江西同和药业股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.jxsynergy.com
    企业联系电话:021-62886322 0795-4605771👤
    📞江西同和药业股份有限公司 ⚠️参考联系方式

    电话:021-62886322 0795-4605771

    传真:+86-795-4605772
    邮箱:sales@jxsynergy.com
    通信地址: 江西省奉新县奉新工业园区
    邮编: 330700
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江西省奉新县奉新工业园区
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ganesh M, Jeon UJ, Ubaidulla U, Hemalatha P, Saravanakumar A, Peng MM, Jang HT. Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. Int J Biol Macromol. 2015 Mar;74:310-7. doi: 10.1016/j.ijbiomac.2014.12.038. doi: 10.1007/s12272-014-0350-4. doi: 10.1186/s13167-015-0047-x.
    5: Galligan TH, Taggart MA, Cuthbert RJ, Svobodova D, Chipangura J, Alderson D, Prakash VM, Naidoo V. Metabolism of aceclofenac in cattle to vulture-killing diclofenac. Conserv Biol. 2016 Oct;30(5):1122-7. doi: 10.1111/cobi.12711. doi: 10.1016/j.clinthera.2013.08.012. doi: 10.3904/kjim.2015.30.5.602.
    8: Jana S, Samanta A, Nayak AK, Sen KK, Jana S. Novel alginate hydrogel core-shell systems for combination delivery of ranitidine HCl and aceclofenac. Int J Biol Macromol. 2015 Mar;74:85-92. doi: 10.1016/j.ijbiomac.2014.11.027. doi: 10.1185/03007995.2013.795139. doi: 10.1016/j.ijpharm.2013.12.017. doi: 10.5792/ksrr.2014.26.1.33.

    合成参考文献


    参考文献:10.1186/1471-2288-5-37
    摘要:Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Medical Research Methodology. 2005 Dec 01;5(1):37. doi: 10.1186/1471-2288-5-37.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知